USFDA gives final approval to Cipla's anti-asthma product

Citing IMS Health data, Cipla said Pulmicort Respules and generic equivalents had US sales of approximately USD 825 million for the 12 months to September 2017.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news